Bayer has made progress in a clinical trial with Asundexian, a drug for the treatment of strokes. Asundexian has blockbuster potential and catapulted the share price up more than 9% on Monday.
Summarized for you
Bayer makes progress with Asundexian, shares up 9%.
Drug lowers stroke risk, FDA fast-track.
Market potential of Asundexian at 3 billion euros.
Report: The year-end rally rolls on
